DOCSLIB.ORG

Cvs Caremark Maintenance Drug List – Rxclaim/Recap

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cvs Caremark Maintenance Drug List – Rxclaim/Recap CVS CAREMARK MAINTENANCE DRUG LIST –RXCLAIM/RECAP AS OF 07/01/2009 Provided below is a reference of the CVS Caremark proprietary list of standard maintenance drugs. Our Maintenance Drug List (MDL) includes medicines commonly used to treat chronic disease states with no therapeutic endpoint. In other words, therapy with these drugs is not considered curative. Maintenance drug categories include but are not limited to Proton Pump Inhibitors, Non-Sedating Antihistamines, Contraceptives, Antidepressants and Diabetic Supplies. The baseline MDL includes Maintenance Drugs as indicated by Medi-Span®. RECAP clients do not utilize the Medi-Span indicator, however this list represents a close approximation of the maintenance medications used on that platform. The extended MDL accommodate CVS Caremark Business rules and federal laws. This list is used as a reference for all applicable CVS Caremark Clinical programs. To make sure the list is up to date, it is reviewed and updated daily (by an external source) as well as quarterly (by CVS Caremark Clinical staff). Below is an example of drugs which may appear on the list. Where a generic is available, it is listed by the generic name. If no generic is available, then the brand name appears. BASE LINE ABACAVIR AMANTADINE AURANOFIN ACAMPROSATE AMARYL AVALIDE ACARBOSE AMILORIDE AVANDAMET ACCOLATE AMINOPHYLLINE AVANDARYL ACCUPRIL AMIODARONE AVANDIA ACCURETIC AMITIZA AVAPRO ACEBUTOLOL AMLODIPINE/BENAZEPRIL AVODART ACEON AMLODIPINE AYGESTIN ACETAZOLAMIDE AMPRENAVIR AZASAN ACTIVELLA AMYLASE-LIPASE AZATHIOPRINE ACTONEL ANAGRELIDE AZILECT ACTOPLUS MET ANAKINRA AZMACORT ACTOS ANAPROX AZOR ADALAT CC ANDROID AZULFIDINE ADALIMUMAB ANDROXY BACLOFEN ADEFOVIR DIPIVOXIL ANSAID BENAZEPRIL ADVAIR ANTARA BENICAR ADVICOR APIDRA BENZTROPINE AEROBID ARAVA MESYLATE AFEDITAB ARCALYST BETAPACE AGGRENOX ARICEPT BETAXOLOL AGRYLIN ARIMIDEX BIDIL ALBUTEROL ARMOUR THYROID BIMATOPROST ALDACTAZIDE AROMASIN BISOPROLOL ALDACTONE ARTHROTEC BONIVA ALENDRONATE ASMANEX BRETHINE ALLOPURINOL ATACAND BRIMONIDINE TARTRATE ALORA ATAMET BRINZOLAMIDE ALTACE ATAZANAVIR BROMOCRIPTINE ALTOPREV ATENOLOL BROVANA ALVESCO ATROPINE SULFATE BUMETANIDE – 1 – 106-15818b 0609 This drug list represents a summary of prescription coverage. It is not inclusive and does not guarantee coverage. Specific prescription benefit plan design may not cover certain categories, regardless of their appearance on this list. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark. BUMEX COVERA ELDEPRYL BUPROPION CREON EMTRICITABINE BYETTA CRESTOR ENABLEX BYSTOLIC CROMOLYN ENALAPRIL CADUET CYANOCOBALAMIN ENFUVIRTIDE CALAN CYCLOSPORINE ENJUVIA CALCITRIOL CYTOMEL ENTECAVIR CAPOTEN DAPSONE EPINEPHRINE CAPTOPRIL DARUNAVIR EPITOL CARBODOPA/LEVODOPA DAYPRO EPLERENONE CARBACHOL OPHTH DDAVP ERGOCALCIFEROL CARBAMAZEPINE DELAVIRDINE MESYLATE ERGOLOID MESYLATES CARBATROL DEMADEX ESCITALOPRAM CARDENE DEMECARIUM BROMIDE ESOMEPRAZOLE CARDIZEM DEPAKENE ESSIAN CARDURA DEPAKOTE ESTERIFIED ESTROGEN CARTEOLOL DESMOPRESSIN ESTRACE CARTIA DESOGESTREL ESTRADERM CARTROL DESVENLAFAXINE ESTRADIOL CARVEDILOL DETROL ESTRATEST CATAFLAM DIABETA ESTRIOL CATAPRES DIABINESE ESTROPIPATE CELEBREX DIAMOX ETANERCEPT CELLCEPT DIAMOX SEQUELS ETHINYL ESTRADIOL CENESTIN DIAZOXIDE ETHOSUXIMIDE CEVIMELINE DICLOFENAC ETHYNODIOL DIACETATE CHLORDIAZEPOXIDE DIDANOSINE ETONOGESTREL CHLORMADINONE DIFLUNISAL ETORICOXIB CHLOROQUINE DIGOXIN ETRAVIRINE PHOSPHATE DILACOR EVAMIST CHLOROTHIAZIDE DILANTIN EVISTA CHLORTHALID DILATRATE EXELON CHOLESTYRAMINE DILTIAZEM EXFORGE CILOSTAZOL DIOVAN FAMOTIDINE CIMETIDINE DIPENTUM FARESTON CISAPRIDE DIPIVEFRIN FELBATOL CITALOPRAM DISOPYRAMIDE FELDENE CLENBUTEROL DISULFIRAM FELODIPINE CLIMARA DITROPAN FEMARA CLINORIL DIVALPROEX FEMHRT CLODRONATE DISODIUM DORNASE FEMTRACE CLONAZEPAM DORZOLAMIDE FENOFIBRATE CLONIDINE DOXAZOSIN FENOGLIDE CLORPRES DROSPIRENONE FENOPROFEN COGNEX DUETACT FENOTEROL COLESTID DULOXETINE FINASTERIDE COLESTIPOL DYAZIDE FLAVOXATE COMBIPATCH DYGASE FLECAINIDE COMTAN DYNACIRC FLOMAX CORDARONE DYRENIUM FLOVENT COREG EC-NAPROSYN FLUDROCORTISONE CORGARD EDECRIN FLUOXETINE CORZIDE EFAVIRENZ FLURBIPROFEN COVARYX EFFER-K FLUVOXAMINE MALEATE – 2 – 106-15818b 0609 This drug list represents a summary of prescription coverage. It is not inclusive and does not guarantee coverage. Specific prescription benefit plan design may not cover certain categories, regardless of their appearance on this list. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark. FOLIC ACID ISOCHRON LOVAZA FORADIL ISONIAZID LUFYLLIN FORTAMET ISOPTIN LYRICA FORTICAL ISORDIL MAGNESIUM FOSAMAX ISOSORB MAPROTILINE FOSAMPRENAVIR ISOSORBIDE DINITRATE MAVIK FOSINOPRIL ISOXSUPRINE MAXZIDE FOSRENOL ISRADIPINE MEBARAL FUROSEMIDE JANUMET MECLOFEN SOD GABAPENTIN JANUVIA MEDROXYPROGESTERONE GABARONE K-DUR MEGESTROL ACETATE GABITRIL KEPPRA MELOXICAM GALANTAMINE KERLONE MEMANTINE GANCICLOVIR KETOPROFEN MENEST GEMFIBROZIL KLONOPIN MENOSTAR GLATIRAMER ACETATE K-LOR MESALAMINE GLIMEPIRIDE KLOR-CON METAGLIP GLIPIZIDE/METFORMIN K-TABS METAPROTERENOL GLIPIZIDE KUVAN METFORMIN GLUCOPHAGE LABETALOL METHAZOLAMIDE GLUCOTROL LACTULOSE METHIMAZOLE GLUCOVANCE LAMICTAL METHITEST GLUMETZA LAMIVUDINE METHOTREXATE GLYBURIDE/METFORMIN LAMOTRIGINE METHYCLOTHIA GLYBURIDE LANOXIN METHYLDOPA GLYCRON LANSOPRAZOLE METIPRANOLOL GLYNASE LANTUS METOCLOPRAMIDE GLYSET LAPASE METOLAZONE GUANABENZ LASIX METOPROLOL GUANFACINE LATANOPROST MEVACOR HECTOROL LEFLUNOMIDE MEXILETINE HOMATROPINE LESCOL MIACALCIN HUMALOG LETAIRIS MICARDIS HUMULIN LEVALBUTEROL MICRO-K HYDRALAZINE LEVATOL MICRONASE HYDROCHLOROTHIAZIDE LEVEMIR MICROZIDE HYOSCYAMINE SULFATE LEVOBETAXOLOL MIDOL HYTRIN LEVOBUNOLOL MINIPRESS HYZAAR LEVOCARNITINE MINITRAN IBUPROFEN LEVOTHYROXINE MINOXIDIL ILOPROST LEVOXYL MIRAPEX IMDUR LIPITOR MIRTAZAPINE IMURAN LIPRAM MISOPROSTOL INCRELEX LISINOPRIL MOBIC INDAPAMIDE LITHIUM MOCLOBEMIDE INDERAL LA LODINE MOEXIPRIL INDINAVIR SULFATE LOFIBRA MONOKET INDOMETHACIN LOPID MONOPRIL INNOPRAN LOPINAVIR MYCOPHENOLATE INSPRA LOPRESSOR MOFETIL INTERFERON LOTENSIN MYFORTIC IPRATROPIUM LOTREL NABUMETONE ISMO LOTRONEX NADOLOL ISOCARBOXAZID LOVASTATIN NALFON – 3 – 106-15818b 0609 This drug list represents a summary of prescription coverage. It is not inclusive and does not guarantee coverage. Specific prescription benefit plan design may not cover certain categories, regardless of their appearance on this list. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark. NAMENDA PAPAVERINE QUINARETIC NAPRELAN PARCOPA QUINIDINE NAPROXEN PARLODEL QVAR NATURE-THROID PAROXETINE RABEPRAZOLE SODIUM NEFAZODONE PENTOXIFYLLINE RALTEGRAVIR NELFINAVIR MESYLATE PENTOXIL RAMIPRIL NEORAL PERFOROMIST RANEXA NEURONTIN PERSANTINE RANITIDINE NEVIRAPINE PHENELZINE SULFATE RAPAMUNE NIACIN PHENOBARB RAUWOLFIA NIASPAN PHENOBARBITAL RAZADYNE NICARDIPINE PHENYTEK REBOXETINE MESYLATE NIFEDIAC PHENYTOIN RENAGEL NIFEDICAL PHOSLO REQUIP NIFEDIPINE PHYSOSTIGMINE RESERPINE NIMODIPINE PILOCARPINE REVATIO NIMOTOP PINDOLOL RILUTEK NISOLDIPINE PIROXICAM RITONAVIR NITISINONE PLARETASE RIVASTIGMINE NITRO-BID PLAVIX ROPINIROLE NITRO-DUR PLENDIL ROZEREM NITROGLYCERIN PLETAL RYTHMOL NIZATIDINE PONSTEL SACROSIDASE NORETHINDRONE POTASSIUM SALSALATE NORETHYNODREL PRANDIN SANCTURA NORGESTIMATE PRAVASTATIN SANDIMMUNE NORGESTREL PRAZOSIN SAQUINAVIR NORPACE PRECOSE SECTRAL NORTHYX PREFEST SELEGILINE NORVASC PREMARIN SENSIPAR NOVOLIN PREMPHASE SEREVENT NOVOLOG PREMPRO SERTRALINE NOXAFIL PREVACID SIMCOR OCTREOTIDE ACETATE PREVALITE SIMVASTATIN OGEN PRIMIDONE SINEMET OLSALAZINE PRINIVIL SINGULAIR OMEPRAZOLE PRINZIDE SIROLIMUS ORENCIA PROBENECID SLO-PHYLLIN ORTHO-EST PROCAINAMIDE SOLTAMOX ORUDIS PROCANBID SOMATROPIN OTILONIUM BROMIDE PROCARDIA SORINE OXAPROZIN PROCYCLIDINE SOTALOL OXCARBAZEPINE PROGRAF SPIRIVA OXTRIPHYLLINE PRONESTYL SPIRONOLACTONE OXYBUTYNIN PROPAFENONE STALEVO OXYTROL PROPRANOLOL STARLIX PACERONE PROPYLTHIOUR STAVUDINE PANCREASE PROSCAR STAVZOR PANCRECARB PROVERA STRATTERA PANCRELIPASE PROVIGIL SUCRALFATE PANCRON PROVIL SULAR PANGES PULMICORT SULFASALAZINE PANGESTYM QUESTRAN SULFAZINE PANTOPRAZOLE QUINAPRIL SULINDAC – 4 – 106-15818b 0609 This drug list represents a summary of prescription coverage. It is not inclusive and does not guarantee coverage. Specific prescription benefit plan design may not cover certain categories, regardless of their appearance on this list. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark. SYMBICORT TIZANIDINE VASERETIC SYMLIN TOLAZAMIDE VASODILAN SYMLINPEN TOLBUTAMIDE VASOTEC SYNTHROID TOLMETIN VENLAFAXINE TAMBOCOR TOPAMAX VENTOLIN TAMOXIFEN TOPROL VERAPAMIL TAPAZOLE TORADOL ORAL VERELAN TARKA TORSEMIDE VESICARE TASMAR TRACLEER VIOKASE TAZTIA TRANDATE VIVELLE-DOT TEGRETOL TRANDOLAPRIL VOLTAREN TEKTURNA TRANYLCYPROMINE VOSPIRE ER TELBIVUDINE TRAVOPROST VYTORIN TENEX TRAZODONE WELCHOL TENOFOVIR DISOPROXIL TRENTAL WELLBUTRIN TENORETIC TRICOR ZALCITABINE TENORMIN TRIHEXYPHENIDATE ZANAFLEX TERAZOSIN TRILEPTAL ZARONTIN TERBUTALINE TRILOSTANE ZAROXOLYN TERIPARATIDE TRIMETHADIONE ZAVESCA TESTOSTERONE ULTRASE ZEBETA TESTRED UNIPHYL ZELAPAR TEVETEN
Load more

Recommended publications
  • Isopropamide Iodide
    www.chemicalland21.com ISOPROPAMIDE IODIDE SYNONYMS (3-Carbamoyl-3,3-diphenylpropyl)diisopropylmethylammonium iodide; 2,2-Diphenyl-4- diisopropylaminobutyramide methiodide; 4-(Diisopropylamino)-2,2-diphenylbutyramide methiodide; gamma-(Aminocarbonyl)-N-methyl-N,N-bis(1-methylethyl)-gamma-phenylbenzenepropanaminium iodide; Iodure d'isopropamide; Ioduro de isopropamida; Isopropamide ioduro; Isopropamidi iodidum; Isoproponum iodide; PRODUCT IDENTIFICATION CAS RN 71-81-8 EINECS RN 200-766-8 FORMULA C23H33IN2O MOL WEIGHT 480.43 PHYSICAL AND CHEMICAL PROPERTIES PHYSICAL STATE white to off-white powder MELTING POINT 199 C BOILING POINT DENSITY SOLUBILITY IN WATER pH VAPOR DENSITY REFRACTIVE INDEX FLASH POINT GENERAL DESCRIPTION Isopropamide is a long-acting anticholinergic and antimuscarinic drug of quaternary ammonium structure. It is used in the form of the iodide, (also bromide or chloride) to treat peptic ulcer and to suppress gastric secretion other gastrointestinal disorders. Brands of Isopropamide drugs: Darbid Dipramide Isamide Marygin-M Piaccamide Priamide Priazimide Sanulcin Tyrimide Quaternary ammonium anticholinergics (Synthetic) ATC Code Product CAS RN. A03AB01 Benzilonium bromide 1050-48-2 A03AB02 Glycopyrrolate 596-51-0 A03AB03 Oxyphenonium 14214-84-7 A03AB04 Penthienate 22064-27-3 A03AB05 Propantheline 50-34-0 A03AB06 Otilonium bromide 26095-59-0 A03AB07 Methantheline 5818-17-7 Please mail us if you want to sell your product or need to buy some products) www.chemicalland21.com ISOPROPAMIDE IODIDE A03AB08 Tridihexethyl 60-49-1 A03AB09 Isopropamide 7492-32-2 A03AB10 Hexocyclium 6004-98-4 A03AB11 Poldine 596-50-9 A03AB12 Mepenzolic acid 25990-43-6 A03AB13 Bevonium 33371-53-8 A03AB14 Pipenzolate 13473-38-6 A03AB15 Diphemanil methylsulfate 62-97-5 A03AB16 (2-Benzhydryloxyethyl)diethyl-methylammonium iodide A03AB17 Tiemonium iodide 144-12-7 A03AB18 Prifinium bromide 4630-95-9 A03AB19 Timepidium bromide 35035-05-3 A03AB21 Fenpiverinium bromide 125-60-0 03AB53 Oxyphenonium, combinations STABILITY AND REACTIVITY STABILITY Stable under normal conditions.
    [Show full text]
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • WITHOUTUS010307409B2 (12 ) United States Patent ( 10 ) Patent No
    WITHOUTUS010307409B2 (12 ) United States Patent ( 10 ) Patent No. : US 10 , 307 ,409 B2 Chase et al. (45 ) Date of Patent: Jun . 4 , 2019 ( 54 ) MUSCARINIC COMBINATIONS AND THEIR (52 ) U . S . CI. USE FOR COMBATING CPC . .. .. A61K 31/ 4439 (2013 . 01 ) ; A61K 9 /0056 HYPOCHOLINERGIC DISORDERS OF THE (2013 . 01 ) ; A61K 9 / 7023 ( 2013 . 01 ) ; A61K CENTRAL NERVOUS SYSTEM 31 / 166 ( 2013 . 01 ) ; A61K 31 / 216 ( 2013 . 01 ) ; A61K 31 /4178 ( 2013 .01 ) ; A61K 31/ 439 (71 ) Applicant: Chase Pharmaceuticals Corporation , ( 2013 .01 ) ; A61K 31 /44 (2013 . 01 ) ; A61K Washington , DC (US ) 31/ 454 (2013 .01 ) ; A61K 31/ 4725 ( 2013 .01 ) ; A61K 31 /517 (2013 .01 ) ; A61K 45 / 06 ( 72 ) Inventors : Thomas N . Chase , Washington , DC (2013 . 01 ) (US ) ; Kathleen E . Clarence -Smith , ( 58 ) Field of Classification Search Washington , DC (US ) CPC .. A61K 31/ 167 ; A61K 31/ 216 ; A61K 31/ 439 ; A61K 31 /454 ; A61K 31 /4439 ; A61K (73 ) Assignee : Chase Pharmaceuticals Corporation , 31 /4175 ; A61K 31 /4725 Washington , DC (US ) See application file for complete search history. ( * ) Notice : Subject to any disclaimer, the term of this (56 ) References Cited patent is extended or adjusted under 35 U . S . C . 154 (b ) by 0 days . U . S . PATENT DOCUMENTS 5 ,534 ,520 A 7 / 1996 Fisher et al. ( 21) Appl . No. : 15 /260 , 996 2008 /0306103 Al 12 /2008 Fisher et al. 2011/ 0021503 A1* 1/ 2011 Chase . .. A61K 31/ 27 ( 22 ) Filed : Sep . 9 , 2016 514 / 215 2011/ 0071135 A1 * 3 / 2011 Chase . .. .. .. A61K 31/ 166 (65 ) Prior Publication Data 514 / 215 2011 /0245294 Al 10 / 2011 Paborji et al.
    [Show full text]
  • Brimonidine Tartrate; Brinzolamide
    Contains Nonbinding Recommendations Draft Guidance on Brimonidine Tartrate ; Brinzolamide This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs. Active Ingredient: Brimonidine tartrate; Brinzolamide Dosage Form; Route: Suspension/drops; ophthalmic Strength: 0.2%; 1% Recommended Studies: One study Type of study: Bioequivalence (BE) study with clinical endpoint Design: Randomized (1:1), double-masked, parallel, two-arm, in vivo Strength: 0.2%; 1% Subjects: Males and females with chronic open angle glaucoma or ocular hypertension in both eyes. Additional comments: Specific recommendations are provided below. ______________________________________________________________________________ Analytes to measure (in appropriate biological fluid): Not applicable Bioequivalence based on (95% CI): Clinical endpoint Additional comments regarding the BE study with clinical endpoint: 1. The Office of Generic Drugs (OGD) recommends conducting a BE study with a clinical endpoint in the treatment of open angle glaucoma and ocular hypertension comparing the test product to the reference listed drug (RLD), each applied as one drop in both eyes three times daily at approximately 8:00 a.m., 4:00 p.m., and 10:00 p.m. for 42 days (6 weeks). 2. Inclusion criteria (the sponsor may add additional criteria): a. Male or nonpregnant females aged at least 18 years with chronic open angle glaucoma or ocular hypertension in both eyes b.
    [Show full text]
  • Muscarinic Acetylcholine Receptor
    mAChR Muscarinic acetylcholine receptor mAChRs (muscarinic acetylcholine receptors) are acetylcholine receptors that form G protein-receptor complexes in the cell membranes of certainneurons and other cells. They play several roles, including acting as the main end-receptor stimulated by acetylcholine released from postganglionic fibersin the parasympathetic nervous system. mAChRs are named as such because they are more sensitive to muscarine than to nicotine. Their counterparts are nicotinic acetylcholine receptors (nAChRs), receptor ion channels that are also important in the autonomic nervous system. Many drugs and other substances (for example pilocarpineand scopolamine) manipulate these two distinct receptors by acting as selective agonists or antagonists. Acetylcholine (ACh) is a neurotransmitter found extensively in the brain and the autonomic ganglia. www.MedChemExpress.com 1 mAChR Inhibitors & Modulators (+)-Cevimeline hydrochloride hemihydrate (-)-Cevimeline hydrochloride hemihydrate Cat. No.: HY-76772A Cat. No.: HY-76772B Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic receptor agonist, is a candidate therapeutic drug for receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR The general pharmacol. properties of this drug on the The general pharmacol. properties of this drug on the gastrointestinal, urinary, and reproductive systems and other… gastrointestinal, urinary, and reproductive systems and other… Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 1 mg, 5 mg 1 mg, 5 mg AC260584 Aclidinium Bromide Cat. No.: HY-100336 (LAS 34273; LAS-W 330) Cat.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • The Role of Antispasmodics in Managing Irritable Bowel Syndrome
    DOI: https://doi.org/10.22516/25007440.309 Review articles The role of antispasmodics in managing irritable bowel syndrome Valeria Atenea Costa Barney,1* Alan Felipe Ovalle Hernández.1 1 Internal Medicine and Gastroenterology specialist Abstract in San Ignacio University Hospital, Pontificia Universidad Javeriana, Bogotá, Colombia. Although antispasmodics are the cornerstone of treating irritable bowel syndrome, there are a number of an- tispasmodic medications currently available in Colombia. Since they are frequently used to treat this disease, *Correspondence: [email protected] we consider an evaluation of them to be important. ......................................... Received: 26/10/18 Keywords Accepted: 11/02/19 Antispasmodic, irritable bowel syndrome, pinaverium bromide, otilonium bromide, Mebeverin, trimebutine. INTRODUCTION consistency. The criteria must be met for three consecutive months prior to diagnosis and symptoms must have started Irritable bowel syndrome (IBS) is one of the most fre- a minimum of six months before diagnosis. (3, 4) quent chronic gastrointestinal functional disorders. It is There are no known structural or anatomical explanations characterized by recurrent abdominal pain associated with of the pathophysiology of IBS and its exact cause remains changes in the rhythm of bowel movements with either or unknown. Nevertheless, several mechanisms have been both constipation and diarrhea. Swelling and bloating are proposed. Altered gastrointestinal motility may contribute frequent occurrences. (1) to changes in bowel habits reported by some patients, and a IBS is divided into two subtypes: predominance of cons- combination of smooth muscle spasms, visceral hypersen- tipation (20-30% of patients) and predominance of dia- sitivity and abnormalities of central pain processing may rrhea (20-30% of patients).
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • 2020 Welldyne Formulary.Pdf
    LEGEND TIER DESCRIPTION 1 Preferred Generics 2 Non-Preferred Generics 3 Preferred Brands 4 Non-Preferred Brands 5 Preferred Specialty 6 Non-Preferred Specialty TYPE DESCRIPTION There is a limit on the amount of this drug that is covered per QL Quantity Limit prescription, or within a specific time frame. You (or your physician) are required to get prior authorization before PA Prior Authorization you fill your prescription for this drug. Without prior approval, we may not cover this drug. In some cases, you may be required to first try certain drugs to treat ST Step Therapy your medical condition before we will cover another drug for that condition. This prescription drug may only be covered if you meet the minimum AL1 Age Limit or maximum age limit. LA Limited Access This prescription drug is limited to certain pharmacies. Specialty drugs are high-cost drugs used to treat complex or rare S Specialty Drug conditions, such as multiple sclerosis, rheumatoid arthritis, hepatitis C, and hemophilia. PAGE 1 LAST UPDATED 01/2020 LIST OF COVERED PRESCRIPTION MEDICATIONS PRODUCT DESCRIPTION TIER LIMITS & RESTRICTIONS ADHD/ANTI-NARCOLEPSY /ANTI-OBESITY/ANOREXIANT AGENTS ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIANTS ADDERALL 4 AL1 Up to 25 yrs old ADDERALL XR 4 AL1 Up to 25 yrs old QL 30 / 30 day(s) ADHANSIA XR 4 AL1 Up to 25 yrs old QL 30 / 30 Days ADIPEX-P 4 PA QL 300 / 30 day(s) ADZENYS ER 4 AL1 Up to 25 yrs old QL 30 / 30 Days ADZENYS XR-ODT 4 AL1 Up to 25 yrs old QL 300 / 30 day(s) AMPHETAMINE ER 4 AL1 Up to 25 yrs old QL 180 / 30 day(s) amphetamine
    [Show full text]
  • Levobetaxolol Hydrochloride
    1882 Miotics Mydriatics and Antiglaucoma Drugs if necessary 5 to 10 minutes later. In the treatment of uveitis Herpes simplex dendritic keratitis developed in 2 patients during Levobetaxolol Hydrochloride (USAN, rINNM) ⊗ (p.1515), the eye drops should be instilled two or three times dai- latanoprost therapy.3 The author suggested that the biochemical ly, or up to every 3 to 4 hours if required. changes in the cornea caused by latanoprost may predispose to AL-1577A (levobetaxolol or levobetaxolol hydrochloride); Hid- herpes keratitis. rocloruro de levobetaxolol; Lévobétaxolol, Chlorhydrate de; The BNFC recommends that eye drops containing 0.5% homat- Levobetaxololi Hydrochloridum. (−)-(S)-1-{p-[2-(Cyclopropyl- ropine hydrobromide are used once daily or on alternate days for 1. Wardrop DRA, Wishart PK. Latanoprost and cystoid macular methoxy)ethyl]phenoxy}-3-isopropylaminopropan-2-ol hydro- uveitis in children aged 3 months to 2 years; older children may oedema in a pseudophake. Br J Ophthalmol 1998; 82: 843–4. be given 1 or 2% eye drops twice daily. 2. Stewart O, et al. Bilateral optic disc oedema associated with chloride. latanoprost. Br J Ophthalmol 1999; 83: 1092–3. Левобетаксолола Гидрохлорид Homatropine has also been used as the quaternary ammonium 3. Ekatomatis P. Herpes simplex dendritic keratitis after treatment methobromide derivative in the treatment of gastrointestinal with latanoprost for primary open angle glaucoma. Br J Ophthal- C18H29NO3,HCl = 343.9. spasm and as an adjunct in peptic ulcer disease; homatropine mol 2001; 85: 1008–9. CAS — 93221-48-8 (levobetaxolol); 116209-55-3 (levo- betaxolol hydrochloride). methobromide has also been included in preparations used for Systemic effects.
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]